| 摘要 |
The present invention concerns the field of urology. The invention provides a novel pharmaceutical composition, comprising a pharmaceutically effective combination of (i) a first compound selected from the group consisting of muscarinic receptor antagonists, 5alpha-reductase inhibitors, and alpha-adrenergic receptor antagonists, and precursors and pharmaceutically acceptable salts thereof, and (ii) a second compound selected from the group consisting of 5-HT1a receptor agonists and antagonists, and precursors and pharmaceutically acceptable salts thereof, and optionally a pharmaceutically acceptable carrier or diluent therefor. There is also provided a method of therapeutical treatment of urinary disorder in a mammal, including man, comprising administering to said mammal, including man, in need of such treatment, a therapeutically effective amount of a composition according to the invention. |
